Surgical management of thyroid carcinoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 3, 2005, Pages 458-466

  Kouvaraki, Maria A ^a,b   Shapiro, Suzanne E ^a,b   Lee, Jeffrey E ^a,b   Evans, Douglas B ^a,b   Perrier, Nancy D ^a,b  

^a University of Texas M D Anderson Cancer Center ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Differentiated thyroid carcinoma; Fine needle aspiration; Medullary thyroid carcinoma; Papillary

Indexed keywords

CALCITONIN;

ANAPLASTIC CARCINOMA; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER RISK; CANCER STAGING; ECHOGRAPHY; FAMILIAL CANCER; HUMAN; LYMPHADENECTOMY; NEEDLE BIOPSY; RECURRENT CANCER; THYROID CARCINOMA; THYROIDECTOMY; TOTAL QUALITY MANAGEMENT; METHODOLOGY; REVIEW; THYROID TUMOR; TUMOR RECURRENCE;

BIOPSY, FINE-NEEDLE; HUMANS; NEOPLASM RECURRENCE, LOCAL; THYROID NEOPLASMS; THYROIDECTOMY; ULTRASONOGRAPHY;

EID: 24944575376     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0022     Document Type: Article

References (66)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-1463.
3. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-885.
4. Simon D, Goretzki PE, Witte J, et al. Incidence of regional recurrence guiding radically in differentiated thyroid carcinoma. World J Surg 1996;20:860-866; discussion 866.
5. Kallinowski F, Buhr HJ, Meybier H, et al. Medullary carcinoma of the thyroid-therapeutic strategy derived from fifteen years of experience. Surgery 1993;114:491-496.
6. Mazzaferri EL. NCCN thyroid carcinoma practice guidelines. Oncology (Huntingt) 1999;13(11A):391-442.
7. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-518.
8. Esnaola NF, Cantor SB, Sherman SI, et al. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 2001;130:921-930.
9. Tyler DS, Shaha AR, Udelsman RA, et al. Thyroid cancer: 1999 update. Ann Surg Oncol 2000;7:376-398.
10. Roman SA. Endocrine tumors: evaluation of the thyroid nodule. Curr Opin Oncol 2003;15:66-70.
11. Sherman SI, Ball DW, Beenken SW, et al. NCCN Oncology Practice Guidelines v.1.2003. Up-to-date version available at http://www.nccn.org. Accessed April 2005.
12. Liel Y, Ariad S, Barchana M. Long-term follow-up of patients with initially benign thyroid fine-needle aspirations. Thyroid 2001;11:775-778.
13. Sclabas GM, Staerkel GA, Shapiro SE, et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 2003;186:702-709; discussion 709-710.
14. Schlinkert RT, van Heerden JA, Goellner JR, et al. Factors that predict malignant thyroid lesions when fine-needle aspiration is "suspicious for follicular neoplasm". Mayo Clin Proc 1997;72:913-916.
15. Goldstein RE, Netterville JL, Burkey B, et al. Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg 2002;235:656-662; discussion 662-654.
16. Udelsman R, Westra WH, Donovan PI, et al. Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. Ann Surg 2001;233:716-722.
17. Richards ML, Chisholm R, Bruder JM, et al. Is thyroid frozen section too much for too little? Am J Surg 2002;184:510-514; discussion 514.
18. Paphavasit A, Thompson GB, Hay ID, et al. Follicular and Hurthle cell thyroid neoplasms. Is frozen-section evaluation worthwhile? Arch Surg 1997;132:674-678; discussion 678-680.
19. Tyler DS, Winchester DJ, Caraway NP, et al. Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. Surgery 1994;116:1054-1060.
20. Layfield LJ, Reichman A, Bottles K, et al. Clinical determinants for the management of thyroid nodules by fine-needle aspiration cytology. Arch Otolaryngol Head Neck Surg 1992;118:717-721.
21. Leenhardt L, Hejblum G, Franc B, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999;84:24-28.
22. Mittendorf EA, Tamarkin SW, McHenry CR. The results of ultrasound-guided fine-needle aspiration biopsy for evaluation of nodular thyroid disease. Surgery 2002;132:648-653; discussion 653-644.
23. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 1993;118:282-289.
24. Simeone JF, Daniels GH, Hall DA, et al. Sonography in the follow-up of 100 patients with thyroid carcinoma. AJR Am J Roentgenol 1987;148:45-49.
25. Antonelli A, Miccoli P, Ferdeghini M, et al. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid 1995;5:25-28.
26. Franceschi M, Kusic Z, Franceschi D, et al. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996;37:446-451.
27. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-511.
28. Sherman SI, Angelos P, Ball DW, et al. NCCN Oncology Practice Guidelines v.1.2005. Up-to-date version available at http://www.nccn.org. Accessed April 2005.
29. Baatenburg de Jong RJ, Rongen RJ, Lameris JS, et al. Metastatic neck disease. Palpation vs ultrasound examination. Arch Otolaryngol Head Neck Surg 1989;115:689-690.
30. Bruneton JN, Roux P, Caramella E, et al. Ear, nose, and throat cancer: ultrasound diagnosis of metastasis to cervical lymph nodes. Radiology 1984;152:771-773.
31. Gorges R, Eising EG, Fotescu D, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 2003;16:191-206.
32. Na DG, Lim HK, Byun HS, et al. Differential diagnosis of cervical lymphadenopathy: usefulness of color Doppler sonography. AJR Am J Roentgenol 1997;168:1311-1316.
33. Frasoldati A, Pesenti M, Gallo M, et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003;97:90-96.
34. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 2002;113:241-260.
35. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
36. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-1057; discussion 1057-1058.
37. Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095.
38. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804.
39. Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma: a clinicopathologic study of 105 consecutive patients. Cancer 1992;70:1585-1590.
40. Russell WO, Ibanez ML, Clark RL, et al. Thyroid carcinoma, classification, intraglandular dissemination, and clinicopathological study based upon whole organ sections of 80 glands. Cancer 1963;16:1425-1460.
41. Silverberg SG, Hutter RV, Foote FW Jr. Fatal carcinoma of the thyroid: histology, metastases, and causes of death. Cancer 1970;25:792-802.
42. Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996;20:88-93.
43. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-964; discussion 964-956.
44. Cady B, Sedgwick CE, Meissner WA, et al. Risk factor analysis in differentiated thyroid cancer. Cancer 1979;43:810-820.
45. Kebebew E, Duh QY, Clark OH. Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model. World J Surg 2000;24:1295-1302.
46. Kouvaraki MA, Lee JE, Shapiro SE, et al. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 2004;136:1183-1191.
47. Yen TW, Shapiro SE, Gagel RF, et al. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 2003;134:890-899; discussion 899-901.
48. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134:946-954.
49. Hamming JF, van de Velde CJ, Goslings BM, et al. Preoperative diagnosis and treatment of metastases to the regional lymph nodes in papillary carcinoma of the thyroid gland. Surg Gynecol Obstet 1989;169:107-114.
50. Attie JN, Khafif RA, Steckler RM. Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg 1971;122:464-471.
51. Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994;24:112-121.
52. Moley JF, Dilley WG, DeBenedetti MK. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997;225:734-740; discussion 740-733.
53. Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001;130:1044-1049.
54. Tisell LE, Hansson G, Jansson S, et al. Reoperation in the treatment of asymptomatic metastasizmg medullary thyroid carcinoma. Surgery 1986;99:60-66.
55. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors tor survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998;48:265-273.
56. Gharib H, McConahey WM, Tiegs RD, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc 1992;67:934-940.
57. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-247; discussion 247-250.
58. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984;63:319-342.
59. Pacini F, Romei C, Miccoli P, et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 1995;118:1031-1035.
60. Pierie JP, Muzikansky A, Gaz RD, et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9:57-64.
61. Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335-2342.
62. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-1034.
63. Takashima S, Morimoto S, Ikezoe J, et al. CT evaluation of anaplastic thyroid carcinoma. AJR Am J Roentgenol 1990;154:1079-1085.
64. Venkatesh YS, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321-330.
65. Tennvall J, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 1994;74:1348-1354.
66. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004;10:8594-8602.